Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
Approval is based on positive data from the Phase 3 ECHELON-3 trial
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
He has over 23 years of experience across sectors
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Plans underway to expand screening capacity by 50% for greater accessibility
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Cancer cases in India estimated to reach 1.57 million in 2025
Subscribe To Our Newsletter & Stay Updated
